“Female Viagra” is an informal nickname, not a precise medical category. Addyi (flibanserin) and Vyleesi (bremelanotide) are different prescription medicines with different routes, schedules, warnings, and FDA-labeled uses. Neither is a general performance enhancer or a universal treatment for low desire.
Addyi is an oral medicine taken on a regular schedule; Vyleesi is an injection used as needed under its label. Their approved populations and safety considerations differ. A clinician first considers whether the person’s experience fits the labeled condition and whether medical, medication, psychological, or relationship factors better explain the change.
The phrase “female Viagra” can make a search look simpler than the underlying question. Viagra (sildenafil) is a medicine used for erectile dysfunction and some other conditions. Addyi and Vyleesi do not work as female versions of sildenafil, and they are not interchangeable with each other. They have separate active ingredients, treatment schedules, and prescribing information.
People may search for these products because a change in sexual desire is distressing, because a partner is urging treatment, or because online advertising presents desire as a problem with a quick fix. A respectful evaluation starts with the person’s own distress and goals. Desire varies across people and over time; a difference from a partner’s preference does not by itself establish a disorder.
What the FDA labels say
FDA-approved labeling describes Addyi (flibanserin) for acquired, generalized hypoactive sexual desire disorder (HSDD) in women younger than 65, when low desire causes marked distress or interpersonal difficulty and is not due to a medical or psychiatric condition, relationship problems, or the effects of a drug or other substance. Label language matters: it is not a claim that the medicine is appropriate for anyone who wants more desire.
Vyleesi (bremelanotide) is labeled for acquired, generalized HSDD in premenopausal women when distress is present and the condition is not better explained by another medical or psychiatric condition, relationship difficulty, or a medication or drug. It is delivered by injection before anticipated sexual activity, under product-specific directions. The label does not indicate it for postmenopausal women, men, or to enhance sexual performance.
| Feature | Addyi (flibanserin) | Vyleesi (bremelanotide) |
|---|---|---|
| Route | Oral tablet | Subcutaneous injection |
| Label use pattern | Regular bedtime dosing; follow current prescription information. | Used as needed before anticipated sexual activity, with limits in the label. |
| FDA-labeled population | Women younger than 65 with acquired, generalized HSDD causing distress, not explained by specified other factors. | Premenopausal women with acquired, generalized HSDD causing distress, not explained by specified other factors. |
| Safety issues to discuss | Sleepiness, dizziness, hypotension or fainting risk, liver impairment, alcohol and interacting medicines. | Nausea, injection-site effects, temporary blood-pressure increase; not for certain cardiovascular conditions or uncontrolled hypertension. |
| What the nickname misses | It is not a broad treatment for “low libido,” relationship problems, or sexual performance. | It is not an on-demand equivalent of sildenafil or a treatment for every change in desire. |
The comparison is a starting point, not a substitute for reading the current label. The FDA may update product information, and a clinician or pharmacist should confirm how it applies to a specific patient and prescription.
Why the diagnosis matters before comparing medicines
Both labels focus on acquired, generalized HSDD—meaning a persistent change in desire that occurs across situations and causes clinically significant distress. That is different from a temporary dip during stress, a change associated with pain, a side effect of another medicine, a relationship conflict, or a difference in desire between partners. The label’s exclusions are there because the right response may be to address the underlying factor rather than add a drug.
A clinician may ask when the change began, whether it is situational or generalized, what distress it causes, and whether pain, menopause-related symptoms, depression, anxiety, sleep, chronic illness, trauma, a medication, or relationship safety could be involved. These are sensitive questions. A patient can ask why a question is relevant and request a private conversation.
There is no obligation to take medication just because a partner or an online quiz suggests it. Treatment should reflect the patient’s own goals and consent. If sexual activity is unwanted or unsafe, a medicine aimed at desire is not the right solution to that situation.
Addyi: daily schedule and safety questions
Addyi is taken on a regular bedtime schedule according to its prescription information, not as a one-time pill immediately before sex. The label includes warnings about sedation and the possibility of low blood pressure or fainting, including concerns with alcohol and certain medicines. Liver impairment and strong or moderate CYP3A4 inhibitors are among the important contraindication or interaction issues in the prescribing information.
Because alcohol advice and product labeling have changed over time, do not rely on an old forum post that says alcohol is always forbidden or always safe. Read the current FDA-approved patient information and ask the pharmacist how it applies to your actual alcohol use, dose timing, liver health, and other medicines. Do not combine Addyi with another person’s sedative or use it if a contraindicated medicine is on your list without first speaking to the prescriber.
Ask what to do if you miss a dose, feel extremely sleepy, become dizzy when standing, or faint. Do not take an extra dose to make up for one you skipped. If fainting, severe confusion, difficulty breathing, or another emergency occurs, seek urgent help and tell responders about the medicine and any alcohol or other drugs.
Vyleesi: injection use and cardiovascular considerations
Vyleesi is an injectable medicine used under its label as needed rather than a daily tablet. The patient information describes how and when to administer it and limits how often it should be used. Anyone considering it should receive hands-on instruction from a clinician or pharmacist and read the device instructions; this article is not injection training.
The label warns that Vyleesi can temporarily increase blood pressure and decrease heart rate. It is not recommended for people with uncontrolled hypertension or known cardiovascular disease. Nausea is common in clinical trials, and injection-site reactions and other effects are also described. A person with blood-pressure or heart conditions should disclose them before treatment rather than relying on an online description of who is “usually fine.”
Ask how the medicine may interact with current prescriptions, whether it can affect other oral medicines, and what symptoms require urgent care. If you have chest pain, fainting, severe headache, or a serious allergic reaction, use emergency services. The clinician should explain whether the symptom may be related to the product or needs evaluation for another cause.
What these medicines cannot promise
Neither product guarantees a particular response, relationship outcome, or level of desire. A medicine can affect biological pathways without resolving pain, stress, trauma, sleep problems, side effects from another prescription, or a relationship issue. Ask the clinician what benefit is realistic, how long the trial should be reviewed, and what would lead to stopping or reassessing the plan.
Online testimonials usually leave out selection criteria, other treatments, side effects, and people who did not benefit. A story can help someone formulate a question, but it cannot identify whether Addyi or Vyleesi fits their health history. Use the FDA label and a clinician who can discuss the underlying concern without judgment.
Questions to bring to a clinician
- Does my experience fit the FDA-labeled condition, or could another factor explain it?
- What are the differences in schedule and route for Addyi and Vyleesi?
- How do my medicines, alcohol use, liver health, blood pressure, or heart history matter?
- What result would count as a meaningful benefit to me?
- Which side effects mean I should call, stop according to the label, or seek emergency help?
- Are non-drug approaches or treatment of another cause more appropriate?
For a comparison with a different medicine, see our guide to Cialis side effects. This is not a substitute for Addyi or Vyleesi information, because sildenafil treats a different condition and has different contraindications. Also read our article on sexual-enhancement supplements with hidden drug ingredients before trusting an “all natural” claim.
How to decide whether either medicine is worth discussing
A useful starting point is to describe the experience without adopting a diagnosis from an advertisement. For example: “My interest in sex changed after this event, and it is upsetting to me,” or “My desire is different in some situations but not others.” That helps the clinician distinguish an acquired generalized pattern from a situational change, pain, medication effect, or relationship context. The clinician may ask about depression, anxiety, menopause-related symptoms, chronic illness, sleep, trauma, and the medicines already being used.
Ask what non-drug options or treatment of an underlying cause could help. If vaginal or pelvic pain makes sex uncomfortable, a medicine intended to increase desire may not address the source of distress. If an antidepressant or another prescription may be contributing, changing that medication can have its own risks and must be planned with the prescriber. Do not stop it abruptly in the hope of improving desire.
After reviewing the history, the clinician can explain whether either product matches the FDA-labeled population, what benefit is realistic, and how long a trial should be assessed. If the treatment is not helpful or causes unacceptable effects, ask what the next step is rather than increasing use or combining products. An informed decision includes the option not to start medication.
When the medicine is not a fit
A medicine may not fit when desire changes are caused by another medical condition, a medication, untreated pain, relationship conflict, or a situation where sex is unwanted or unsafe. These are not failures by the patient. They are clues that a different kind of support may be more relevant. A clinician can refer to gynecology, mental-health care, or relationship support when appropriate and when the patient wants it.
Patients can ask for a private conversation and decline to discuss details they are not ready to share. They can also ask how records are protected and who can see them. Sexual health deserves the same careful, consent-based discussion as other health concerns.
Bottom line
“Female Viagra” is an imprecise nickname. Addyi and Vyleesi are distinct medicines with different FDA-labeled populations, routes, schedules, and risks. A clinical discussion should establish whether the person’s concern fits the label, review other causes and medicines, and explain realistic benefits and safety monitoring. Do not start, share, or combine these products based on a nickname or an online testimonial.
Sources and further reading
- FDA: Addyi (flibanserin) prescribing information, 2025
- Vyleesi: Full prescribing information
- FDA: Addyi indication and promotional context
- MedlinePlus: Flibanserin drug information
Evidence checked October 20, 2026. This article does not diagnose a sexual-health condition or recommend a specific prescription.